Non-Small Cell Lung Cancer

Latest News

Joshua K. Sabari, MD | Image: NYU Langone
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

July 1st 2025

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

FDA Approved | Image Credit: © wladimir1804 - stock.adobe.com
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

June 23rd 2025

FDA Approved | Image Credit: wladimir1804-stock.adobe.com
Taletrectinib Approved for ROS1-Positive NSCLC

June 11th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo